https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%B9%BF%E6%B3%9B%E6%9C%9F_SCLC
广泛期 SCLC - 版本历史
2026-04-19T07:00:55Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%B9%BF%E6%B3%9B%E6%9C%9F_SCLC&diff=316552&oldid=prev
120.244.141.225：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-07T06:01:33Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>广泛期 SCLC</strong>（Extensive-Stage Small Cell Lung Cancer, ES-SCLC）是指肿瘤已超出单侧半胸范围，无法被单个放射野安全覆盖的<strong>[[小细胞肺癌]]</strong>。<br />
<br>这包括出现对侧肺门/纵隔淋巴结转移、恶性胸腔积液/心包积液，或发生<strong>远处转移</strong>（如脑、骨、肝、肾上腺）。约 <strong>70%</strong> 的 SCLC 患者在初诊时即处于广泛期。<br />
<br>ES-SCLC 曾被视为“绝症”，单纯化疗的中位生存期不足 10 个月。随着 <strong>[[免疫治疗]]</strong>（PD-L1 抑制剂）的加入，<strong>“化疗+免疫”</strong>（Chemo-IO）已取代使用了 30 年的 EP 方案，成为新的一线治疗金标准，显著打破了生存瓶颈。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ES-SCLC</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Extensive-Stage Small Cell Lung Cancer</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">全身性疾病的“拉锯战”</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">临床特征</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">定义</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">超出局限期范围 / 远转</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">常见转移</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">脑 (Brain), 肝, 骨, 肾上腺</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">生长速度</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;">极快 (倍增时间 < 30天)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">伴随症状</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[副肿瘤综合征]] (SIADH等)</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">治疗数据</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">一线标准</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;">化疗 (EP) + [[PD-L1抑制剂]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">中位生存期</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">~12 - 13 个月 (IO时代)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">5年生存率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">< 3% (极差)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">二线药物</th><br />
<td style="padding: 6px 12px; color: #1e40af;">[[拓扑替康]], [[芦比替定]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">一线治疗革命：Chemo-IO 模式</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
过去 30 年，依托泊苷+铂类（EP）是唯一选择。如今，<strong>“免疫联合化疗”</strong>（Chemo-Immunotherapy）通过解除肿瘤的免疫抑制，首次在广泛期 SCLC 中实现了生存期的显著延长。<br />
</p><br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">方案名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 45%;">具体组合</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 30%;">关键证据 (Trial)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">A药联合方案</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[阿替利珠单抗]]</strong> (Atezolizumab) <br>+ 卡铂 + 依托泊苷</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>IMpower133</strong><br>首个获批 IO 方案</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">I药联合方案</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[度伐利尤单抗]]</strong> (Durvalumab) <br>+ 顺铂/卡铂 + 依托泊苷</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>CASPIAN</strong><br>提供顺铂联合选择</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">斯鲁利单抗方案</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[斯鲁利单抗]]</strong> (Serplulimab) <br>+ 卡铂 + 依托泊苷</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>ASTRUM-005</strong><br>打破 OS 纪录 (15.4月)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">复发后的困境：敏感 vs. 耐药</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
SCLC 虽然初治有效率高达 60-80%，但几乎不可避免地会在数月内复发。复发时间决定了后续治疗策略。<br />
</p><br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>铂敏感复发 (Sensitive Relapse)：</strong> 指一线化疗结束 <strong>> 3 个月</strong> 后复发。此时肿瘤对铂类仍敏感，标准策略是<strong>原方案再挑战</strong>（Re-challenge）或使用二线药物。</li><br />
<li style="margin-bottom: 12px;"><strong>铂耐药复发 (Resistant Relapse)：</strong> 指一线化疗结束 <strong>< 3 个月</strong> 内复发，或治疗期间进展。预后极差。</li><br />
<li style="margin-bottom: 0;"><strong>二线选择：</strong> 传统的标准药物是<strong>[[拓扑替康]]</strong> (Topotecan)，但毒性大、疗效有限。新型药物<strong>[[芦比替定]]</strong> (Lurbinectedin) 因其较低的血液毒性和稍高的有效率，已获得 FDA 批准用于二线治疗。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">关键相关概念 [Key Concepts]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
<strong>1. Paraneoplastic Syndrome (副肿瘤综合征)：</strong> SCLC 是神经内分泌肿瘤，常分泌异位激素。最常见的是 <strong>[[SIADH]]</strong>（抗利尿激素分泌不当导致低钠血症）和 <strong>Cushing Syndrome</strong>（库欣综合征/ACTH异常）。这往往是 SCLC 的首发表现。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
<strong>2. Consolidative Radiotherapy (巩固性胸部放疗)：</strong> 对于广泛期患者，如果在全身化疗后达到完全缓解或部分缓解，且胸外病灶控制良好，对残留的胸部病灶进行放疗可延长生存期。<br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
<strong>3. Brain Metastasis (脑转移)：</strong> ES-SCLC 患者发生脑转移的风险极高。对于无症状脑转移，首选全身系统治疗；有症状者需行全脑放疗（WBRT）或立体定向放疗（SRS）。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 20px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #ffffff;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Horn L, et al. (2018).</strong> <em>First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.</em> <strong>[[N Engl J Med]]</strong>. <br><br />
<span style="color: #475569;">[点评]：IMpower133 研究。里程碑式文献，首次证实 PD-L1 联合化疗改善了 ES-SCLC 的 OS，结束了该领域 30 年无新药的历史。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Paz-Ares L, et al. (2019).</strong> <em>Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN).</em> <strong>[[The Lancet]]</strong>. <br><br />
<span style="color: #475569;">[点评]：CASPIAN 研究。确立了度伐利尤单抗作为另一项一线标准治疗方案，且显示了长期生存获益（“长尾效应”）。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Trigo J, et al. (2020).</strong> <em>Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.</em> <strong>[[Lancet Oncol]]</strong>. <br><br />
<span style="color: #475569;">[点评]：支持了芦比替定获批用于二线治疗的关键研究，尤其对化疗耐药患者提供了一种新的非铂类选择。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
肺癌诊疗 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级分类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[小细胞肺癌]] (SCLC) • 晚期恶性肿瘤</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[依托泊苷]] • [[卡铂]] • [[阿替利珠单抗]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">对比分期</td><br />
<td style="padding: 10px 15px; color: #334155;">[[局限期 SCLC]] (可根治)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
120.244.141.225